An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

This study has been completed.
Janssen Pharmaceuticals
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated Identifier:
First received: September 27, 2012
Last updated: May 12, 2015
Last verified: May 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2015
  Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)